All In Biotech

Drug Trial Radar · NCT06975748

A Phase II Study of STSP-0902 Ophthalmic Solution in Patients With Neurotrophic Keratitis

A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of STSP-0902 Ophthalmic Solution in Patients With Neurotrophic Keratitis

Last checked: Nov 19, 2026Latest source record: Apr 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

48

Planned (sponsor's estimate)

Start

Jun 12, 2025

Primary completion

Apr 2026

Study completion Apr 2026

Sponsor

Sponsor type
Industry
First posted
May 16, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase II, double-blind, placebo-controlled study to evaluate the safety and efficacy of STSP-0902 ophthalmic solution in patients with neurotrophic keratitis (NK). The study plans to enroll 48 patients with Mackie Stage 2 or 3 NK affecting one or both eyes. Eligible subjects will be randomized 1:1:1 into three dosing groups. Each dosing group will follow a drug-placebo allocation (12 active: 4 placebo). Treatment involves topical ocular administration for 8 weeks. Subjects who are not healed after the 8 weeks of masked treatment period will be permitted to receive standard of care during the follow-up period

Conditions

  • Neurotrophic Keratitis

Interventions

  • STSP-0902 ophthalmic solutionDrug

    Eye drop, 3 times daily for 8 weeks

  • STSP-0902 ophthalmic solutionDrug

    Eye drop, 6 times daily for 8 weeks

  • STSP-0902 PlaceboDrug

    Eye drop, 3 or 6 times daily for 8 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Adverse EventsTime frame: Screening to Week 10
  2. Ocular Symptoms and SignsTime frame: Screening to Week 10
  3. Intraocular Pressure (IOP) MeasurementsTime frame: Screening to Week 10
  4. Slit-Lamp ExaminationsTime frame: Screening to Week 10
  5. Optical Coherence Tomography (OCT) ResultsTime frame: Screening to Week 10
  6. Clinically Significant Changes in Vital SignsTime frame: Screening to Week 10
  7. Clinically Significant Changes in Physical ExaminationsTime frame: Screening to Week 10
  8. Clinically Significant Changes in 12-Lead ECGsTime frame: Screening to Week 10
  9. Clinically Significant Laboratory AbnormalitiesTime frame: Screening to Week 10

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shandong First Medical University Affiliated Eye Hospital

    Jinan, Shandong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.